At a Glance
Main Sequence Ventures was spun out of CSIRO, Australia's national science agency, in 2017 to commercialize breakthrough scientific research and invest in deep tech startups. The firm uniquely combines venture capital with deep scientific expertise, leveraging CSIRO's research capabilities and network to identify and develop companies built on cutting-edge science and technology. Main Sequence focuses on areas including artificial intelligence, climate technology, biotechnology, agriculture, and advanced manufacturing, typically investing from pre-seed through Series A rounds. The firm's approach involves working closely with research institutions, universities, and corporate partners to translate scientific discoveries into viable commercial ventures. Led by partners with backgrounds spanning venture capital, entrepreneurship, and scientific research, Main Sequence has established itself as Australia's leading deep tech investor. The firm's portfolio companies often tackle complex global challenges requiring significant R&D and long development timelines. Their model of combining patient capital with scientific expertise has attracted international attention as a framework for commercializing deep tech innovation in other markets.
“Invests in startups transforming industries through deep technology and scientific breakthroughs, leveraging Australia's world-class research ecosystem.”
Main Sequence Ventures primarily invests at the Pre-Seed, Seed, Series A stages. This means they focus on companies that are at the earliest idea or prototype phase.
Main Sequence Ventures is headquartered in Sydney, Australia. Many of their portfolio companies are also based in this region, though they invest across geographies.
Main Sequence Ventures focuses on investments in Deeptech, AI, Climate, Biotech, Agriculture. Their portfolio reflects deep expertise and networks within these sectors.
Main Sequence Ventures's typical investment check size ranges from $500K to $10M. Actual amounts may vary based on the stage, sector, and specific opportunity.
Main Sequence Ventures manages approximately $350M in assets under management (AUM) across their funds.